CoChat

Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin

Marre, M., Howlett, H., Lehert, P., Allavoine, T. · 2002 · Diabetic Medicine
Cited by 85

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims To evaluate the efficacy and safety of two dosage strengths of a single‐tablet metformin–glibenclamide (glyburide) combination, compared with the respective monotherapies, in patients with Type 2 diabetes mellitus (DM) inadequately controlled by metformin monotherapy. Methods In this 16‐week, double‐blind, multicentre, parallel‐group trial, 411 patients were randomized to receive metformin 500 mg, glibenclamide 5 mg, metformin–glibenclamide 500 mg/2.5 mg or metformin–glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) ≤ 7 mmol/l. Results Decreases in glycated haemoglobin (HbA 1c) and FPG were greater (P < 0.05) for metformin–glibenclamide 500 mg/2.5 mg (−1.20% and −2.62 mmol/l) and 500 mg/5 mg (−0.91% and −2.34 mmol/l), compared with metformin (−0.19% and −0.57 mmol/l) or glibenclamide (−0.33% and −0.73 mmol/l). HbA 1c< 7% was achieved by 75% and 64% of patients receiving metformin–glibenclamide 500 mg/2.5 mg and 500 mg/5 mg, respectively, compared with 42% for glibenclamide and 38% for metformin (P = 0.001). These benefits were achieved at lower mean doses of metformin or glibenclamide with metformin–glibenclamide 500 mg/2.5 mg and 500 mg/5 mg (1225 mg/6.1 mg and 1170 mg/11.7 mg) than with glibenclamide (13.4 mg) or metformin (1660 mg). Treatment‐related serious adverse events occurred in two patients receiving glibenclamide. Plasma lipid profiles were unaffected and mean changes in body weight were ≤ 1.0 kg. Conclusions Intensive management of Type 2 DM with a new metformin–glibenclamide combination tablet improved glycaemic control and facilitated the attainment of glycaemic targets at lower doses of metformin or glibenclamide compared with the respective monotherapies, without compromising tolerability. Diabet. Med. 19, 673–680 (2002)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-5491.2002.00774.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 85

Metadata

Authors
Marre, M., Howlett, H., Lehert, P., & Allavoine, T.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2002-07-30
Volume
19
Issue
8
Pages
673-680
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2151921086
Cited by
85
References
7
FWCI
4.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin. https://app.cochat.ai/papers/10.1046/j.1464-5491.2002.00774.x
The paper
Marre, M., Howlett, H., Lehert, P., & Allavoine, T. (2002). Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2002.00774.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.